The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 11, 2017

Filed:

Mar. 15, 2013
Applicants:

Fundació Institut DE Recerca Biomèdica (Irb Barcelona), Barcelona, ES;

Institució Catalana DE Recerca I Estudis Avançats, Barcelona, ES;

Inventors:

Roger Gomis, Barcelona, ES;

Milica Pavlovic, Lajkovac, RS;

Evarist Planet, Barcelona, ES;

Anna Arnal, Barcelona, ES;

Maria Tarragona, Barcelona, ES;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/574 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5748 (2013.01); C07K 16/2875 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/57415 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4706 (2013.01);
Abstract

The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.


Find Patent Forward Citations

Loading…